Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton, Tyco Blocked RTI's VanishPoint Syringe From Market, Suit Alleges

This article was originally published in The Gray Sheet

Executive Summary

Retractable Technologies, Inc.' s antitrust suit against Becton Dickinson is currently in the discovery phase and unlikely to go to trial before the end of the summer, counsel to the plaintiff indicates.

You may also be interested in...



BD/RTI syringe settlement

Retractable Technologies, Inc. will receive $100 mil. from BD to settle a 1999 lawsuit alleging conspiracy to prevent sales of its VanishPoint retractable syringes. RTI settled with the three other defendants - competitor Tyco Healthcare and hospital group purchasing organizations Premier and Novation - in May 2003, providing access to contracts and financial remuneration (1"The Gray Sheet" March 1, 1999, p. 20)...

BD/RTI syringe settlement

Retractable Technologies, Inc. will receive $100 mil. from BD to settle a 1999 lawsuit alleging conspiracy to prevent sales of its VanishPoint retractable syringes. RTI settled with the three other defendants - competitor Tyco Healthcare and hospital group purchasing organizations Premier and Novation - in May 2003, providing access to contracts and financial remuneration (1"The Gray Sheet" March 1, 1999, p. 20)...

GPO Administrative Stress On Medicare Studied By OIG; Applied Sues Ethicon

The strain imposed by GPO administrative fees on Medicare will be investigated by the HHS Office of the Inspector General, according to OIG's 2004 work plan

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel